Overview

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This phase II study was to assess the efficacy and toxicity of hypofractionated radiotherapy (HRT) combined with weekly docetaxel/platinum and thymosin α1 in patients with unresectable or recurrent thymic epithelia tumors (TETs).
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University